COMPOUNDS Russian patent published in 2012 - IPC C07D473/16 A61K31/52 A61P35/00 A61P31/12 A61P25/28 A61P17/14 A61P5/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new purine derivatives possessing the properties of an inhibitor of the enzyme CDK specified in CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and CDK9. In formula (I): R¹ and R² each independently represents H, C_1-6alkyl or C_1-6halogenalkyl; R³ and R⁴ each independently represents H, C_1-6-alkyl or C_1-6-halogenalkyl; R⁵ represents C_1-6-alkyl or C_3-12-cycloalkyl, or C_3-12-cycloalkyl-C_1-6-alkyl each of which may be optionally substituted by one or more OH groups; R⁶ represents wherein Y represents N, X and Z represents CR⁹; R⁷, R⁸ and R⁹ optionally represent H, alkyl or C_1-6-halogenalkyl; wherein at least one of R⁷ , R⁸ and R⁹ is other than H. The invention also refers to a pharmaceutical composition containing said compounds, using the compounds for treating alopecia, stroke, a proliferative disease, such as cancer, leukaemia, glomerulonephritis, rheumatoid arthritis, psoriasis, viral diseases, such as a disease caused by human cytomegalovirus, type 1 herpex simplex virus, type 1 human immunodeficiency virus, a neurodegenerative disease, a CNS disease, such as Alzheimer's disease.

EFFECT: preparing new purine derivatives possessing the properties of the inhibitor of the enzyme CDK.

30 cl, 8 tbl, 18 ex